KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Cost of Revenue: 2016-2024

Historic Cost of Revenue for Sarepta Therapeutics (SRPT) over the last 9 years, with Dec 2024 value amounting to $319.1 million.

  • Sarepta Therapeutics' Cost of Revenue rose 208.82% to $137.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $406.1 million, marking a year-over-year increase of 130.34%. This contributed to the annual value of $319.1 million for FY2024, which is 112.25% up from last year.
  • Latest data reveals that Sarepta Therapeutics reported Cost of Revenue of $319.1 million as of FY2024, which was up 112.25% from $150.3 million recorded in FY2023.
  • In the past 5 years, Sarepta Therapeutics' Cost of Revenue ranged from a high of $319.1 million in FY2024 and a low of $63.4 million during FY2020.
  • Moreover, its 3-year median value for Cost of Revenue was $150.3 million (2023), whereas its average is $203.1 million.
  • Data for Sarepta Therapeutics' Cost of Revenue shows a peak YoY surged of 112.25% (in 2024) over the last 5 years.
  • Over the past 5 years, Sarepta Therapeutics' Cost of Revenue (Yearly) stood at $63.4 million in 2020, then skyrocketed by 53.12% to $97.0 million in 2021, then skyrocketed by 44.25% to $140.0 million in 2022, then climbed by 7.40% to $150.3 million in 2023, then surged by 112.25% to $319.1 million in 2024.